These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35696864)

  • 21. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.
    Maniar R; Gallitano SM; Husain S; Moazami G; Weiss MJ; Shu CA
    J Natl Compr Canc Netw; 2023 Feb; 21(3):232-234. PubMed ID: 36758579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
    Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
    Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabrafenib and trametinib for the treatment of non-small cell lung cancer.
    Kelly RJ
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1063-1068. PubMed ID: 30198802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encorafenib plus binimetinib in patients with
    Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
    Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.
    Gouda MA; Subbiah V
    ESMO Open; 2023 Apr; 8(2):100788. PubMed ID: 36842301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
    Menzer C; Hassel JC
    Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
    Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
    [No Abstract]   [Full Text] [Related]  

  • 31. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
    Tsamis I; Gomatou G; Chachali SP; Trontzas IP; Patriarcheas V; Panagiotou E; Kotteas E
    Clin Transl Oncol; 2023 Jan; 25(1):10-20. PubMed ID: 35729451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
    Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D
    Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
    Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
    Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
    Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
    Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
    J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report.
    Huang Z; Wang Y; Li B; Xu Y; Huang G; Song Y; Li J; Song L; Wang J; Wang R; Liang N; Li S
    Thorac Cancer; 2024 Aug; 15(24):1825-1828. PubMed ID: 39020500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening.
    Lung J; Hung MS; Lin YC; Jiang YY; Fang YH; Lu MS; Hsieh CC; Wang CS; Kuan FC; Lu CH; Chen PT; Lin CM; Chou YL; Lin CK; Yang TM; Chen FF; Lin PY; Hsieh MJ; Tsai YH
    Sci Rep; 2020 Oct; 10(1):16943. PubMed ID: 33037234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
    Adashek JJ; Menta AK; Reddy NK; Desai AP; Roszik J; Subbiah V
    Mol Cancer Ther; 2022 Jun; 21(6):871-878. PubMed ID: 35413124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
    Wu H; Feng J; Lu S; Huang J
    Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabrafenib Active in Rare NSCLC Subtype.
    Cancer Discov; 2016 Jul; 6(7):OF4. PubMed ID: 27207893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.